Emovi signs endorsement deal with Olympic gold medalist and four-time world champion track and field athlete
Montreal, Quebec (September 4, 2019) Emovi, Inc. today announced that Canadian Olympian Bruny Surin, a KneeKG™ patient, has joined as an official Brand Ambassador and spokesperson for KneeKG, the first in-clinic device that meets the global need for measuring knee function with objective and quantifiable data associated with mechanical knee markers and functional deficiencies.
Bruny Surin won two gold medals in the 60 metres at the World Indoor Championships and two silver medals in the 100 metres at the World Championships. Although Surin also long jumped at the 1988 Olympics and the 1990 Commonwealth Games, he was better known as a sprinter and part of the best 4×100 m relay team in the mid-90s. With the Canadian 4×100 metres relay team, Surin won gold medals at the 1996 Olympics, the 1994 Commonwealth Games, the 1998 Goodwill Games, and the 1995 and 1997 World Championships, adding a bronze at the 1993 Worlds.
Surin began experiencing knee pain in 2014. He was evaluated by his doctor and had a Knee
Kinesiography by KneeKG which led to an immediate diagnosis of a flexion contracture. Being
skeptical, Surin did not fully integrate the recommendations based off the Knee Kinesiography. In 2018, as prevention Surin had another Knee Kinesiography which assisted his doctor in identifying three new factors related to the progression of knee osteoarthritis (OA): dynamic flexion contracture (flexum); static and dynamic varus alignment; and internal tibial rotation while bearing weight.
According to Surin, “the biomechanical explanations were related to exactly how I felt. This direct correlation encouraged me to do the suggested exercises. Indeed, a retest in 2019 showed all the factors related to the progression of OA of the knee had disappeared.”
KneeKG is the first device that enables doctors to accurately assess patients’ knees in 3D while the patient is moving and weight-bearing. In contrast to static information provided by X-ray and magnetic resonance imaging (MRI), KneeKG quickly identifies motion of impaired knees to allow healthcare professionals to determine the most appropriate care pathway to restore optimal knee function. KneeKG is revolutionizing existing knee assessment techniques and is more efficient than the current process of elimination method. By providing technical information to doctors with a higher correlation to symptoms and at a fraction of the cost of high-tech scans such as MRIs, the KneeKG allows doctors to significantly improve patients’ quality of life while reducing pain and functional limitations.
“I’m thrilled to join Emovi in its quest to help people with knee pain and I am eager to endorse KneeKG. It’s an extraordinary device for anyone experiencing knee pain,” said Surin. “KneeKG provided my doctor and physiotherapist pertinent information so they could personalize a treatment plan with effective exercises and a correction to my orthotics.”
Knee pain is the second most common cause of chronic pain in the United States, an affliction affecting one-third of Americans at some time or another. Osteoarthritis is the most common joint disorder in the United States, affecting 13.9% of adults 25 years and older and 33.6% of people 65 years and older.
About Emovi Inc.
Headquartered in Montreal, Emovi is a medical device company that develops products for knee joint assessment to restore patient quality of life. In partnership with the Quebec university research community, including the CRCHUM and École de technologie supérieure (ÉTS), Emovi completed the development of the KneeKG, a unique clinical tool evaluating knee functional deficiencies linked to patients’ symptoms and pathology progression. Emovi owns multiple patents and the exclusive license to commercialize the KneeKG in several countries.